Avro­bio halts PhII study for Fab­ry dis­ease in an­oth­er set­back, shut­ter­ing lead pro­gram

An oft-trou­bled Fab­ry dis­ease pro­gram got the axe Tues­day as its par­ent com­pa­ny will shut down de­vel­op­ment af­ter re­view­ing some new Phase II da­ta. And the news is send­ing shares tum­bling again.

Avro­bio will “de­pri­or­i­tize” the Fab­ry dis­ease can­di­date AVR-RD-01, the com­pa­ny said in a press re­lease Tues­day morn­ing, cit­ing vari­able en­graft­ment pat­terns in new­ly dosed pa­tients from the Phase II tri­al, which has been halt­ed. The biotech al­so said it’s fac­ing tougher than ex­pect­ed com­pe­ti­tion in the Fab­ry dis­ease mar­ket and could face a tougher reg­u­la­to­ry en­vi­ron­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER